Patients With Severe Mental IllnessNCT07448675
Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness
An observational study of Patients With Severe Mental Illness, run by Tianjin Anding Hospital at 1 site in China.
Trial summary
Patients with Severe Mental Illness (SMI) frequently exhibit cognitive impairment of varying degrees, involving multiple cognitive domains. These domains include working memory, attention/vigilance, verbal learning and memory, visual learning and memory, reasoning and problem-solving, processing speed, and social… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Patients With Severe Mental Illness
- How many people
- 230 participants
- Where
- 1 siteChina
- Study dates
- 7 Feb 2023to 30 Jun 2026
- How long will I take part?
- 12 Weeks
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This study will recruit 150 untreated severe mental illness patients and 80 healthy controls. The 150 subjects, aged 18-65, come from Tianjin Anding Hospital's inpatient/outpatient services and must consent to participate. Untreated patients must meet strict criteria: never taking antipsychotics, or taking them for ≤3 days, or >5 years of illness with <30 lifetime treatment days and no use in the last 5 years (TCM for psychosis excluded). The 80 healthy controls will be matched to patients based on age, gender, education, and residence (urban/rural).
Who may be able to join
- Aged 18-65 years;
- Matched to enrolled untreated patients in terms of age, sex, educational attainment, and place of residence (urban or rural).
Who cannot join
- Psychotic symptoms caused by a general medical condition or substance use;
- A history of mental retardation (estimated IQ below 70), dementia, head trauma, or brain disease, a history of seizures (epilepsy), or any history of violent or suicidal tendencies;
- Any factor that prevents the participant from providing informed consent or participating in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Patients with Severe Mental Illness (SMI) frequently exhibit cognitive impairment of varying degrees, involving multiple cognitive domains. These domains include working memory, attention/vigilance, verbal learning and memory, visual learning and memory, reasoning and problem-solving, processing speed, and social cognition. The severity of this impairment often predicts poorer treatment adherence and serves as a crucial indicator of a patient's capacity for independent living and social reintegration. Research into the mechanisms underlying cognitive impairment offers robust theoretical support for therapeutic interventions in SMI and remains a major focus in psychiatry. However, cognitive impairment is a complex phenomenon; studies focusing on any single cognitive dimension can only reveal partial characteristics and often lack disease specificity. Therefore, there is an urgent need to integrate multiple technical modalities, focusing on a specific biological pathway related to the symptoms of cognitive impairment, to deeply elucidate the process of its onset and to screen for reliable biomarkers. This study will recruit untreated SMI patients and healthy community controls. Upon enrollment, participants will undergo comprehensive assessments including psychiatric symptom evaluation, cognitive function testing, Electroencephalography (EEG), Magnetic Resonance Imaging (MRI), and collection of research blood samples. A follow-up assessment will be conducted at 12 weeks, re-evaluating psychiatric symptoms, cognitive functions, and EEG, while collecting follow-up blood samples and medication records. By integrating these assessment indicators, we aim to identify the potential biological mechanisms underlying cognitive dysfunction in untreated SMI patients, construct a predictive and identification model for cognitive impairment, and explore the concomitant changes in biological markers during the evolution of cognitive impairment through longitudinal follow-up, thus paving the way for prospective targeted interventions.
- Conditions
- Patients With Severe Mental Illness
- Keywords
- Patients with Severe Mental Illness, cognitive dysfunction, Untreated, longitudinal follow-up, Biological Mechanism
- Medical subject headings
- Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Untreated Severe Mental Illness (SMI) Patients | We will enroll 150 patients who meet the following inclusion criteria: a current or past episode of a psychotic disorder meeting DSM-5 diagnostic criteria, including Schizophrenia, Schizoaffective Disorder, Acute and Transient Psychotic Disorder, Schizophreniform Disorder, Delusional Disorder, Other Specified or Unspecified Psychotic Disorder, or Bipolar Disorder with psychotic features; age between 18 and 65 years, inclusive; and willingness to participate and sign the informed consent form (ICF); in addition, untreated patients must meet the following specific criteria: no lifetime exposure to antipsychotic medication, or continuous use of antipsychotic medication for a period not exceeding 3 days, or a course of illness exceeding 5 years with no antipsychotic use in the last 5 years and a total lifetime cumulative use of antipsychotic medication of less than 30 days; traditional Chinese medicine used for treating psychotic symptoms will not be counted as antipsychotic medication. | |
| Healthy Control | We will include 80 healthy controls who meet the following criteria: aged 18-65 years and matched to enrolled untreated patients in terms of age, sex, educational attainment, and place of residence (urban or rural). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive Function
Cognitive function will be assessed using the MATRICS Consensus Cognitive Battery (MATRICS-CN). The following domains will be measured: processing speed, verbal learning, working memory, reasoning and problem-solving, visual learning, and attention/alertness. It possesses excellent psychometric properties, correlates with functional outcomes, and is brief, easy to administer, can be used for home-based assessments, is acceptable to participants, and has domain "robustness." The MATRICS-CN has been translated into Chinese and is available for purchase from PAR, Inc.
Measured: Baseline, week12
Secondary outcomes (12)
Positive and Negative Symptom Scale (PANSS)
The psychiatric symptoms of schizophrenia were assessed in all enrolled patients using the Positive and Negative Syndrome Scale (PANSS). The PANSS is a 30-item clinician-rated scale yielding a total score ranging from 30 (least symptomatic) to 210 (symptomatic), where higher scores indicate more severe psychopathology.
Measured: Baseline, week12
Young Mania Rating Scale (YMRS)
This is an 11-item clinician-rated scale (scored from 0-4 or 0-8, depending on the items) that assesses the severity of mania and the response to treatment in patients with bipolar disorder. The assessment is based on clinical observation and patient subjective reports regarding symptoms over the past 48 hours.
Measured: Baseline, week12
Montgomery-Åsberg Depression Rating Scale (MADRS)
This is a 10-item clinician-rated questionnaire (scored 0-6 per item) that assesses the severity of depressive episodes in patients with affective disorders. The assessment is based on the patient's subjective report of their symptoms over the past week.
Measured: Baseline, week12
Global Assessment of Functioning (GAF) Scale
Primarily used to assess the subject's psychological, social, and occupational functioning. The GAF consists of only one dimension: the overall clinical severity level. It is divided into 100 levels (scored from 1-100), where a higher score indicates less severe illness.
Measured: Baseline, week12
Antisaccade Task Error Rate
The antisaccade task consists of 4 blocks of 20 trials each. Each trial begins with a central fixation cross. A peripheral visual target appears at 10° or 15° visual angle from fixation, and the fixation cross disappears 200ms after target onset. Participants are instructed to inhibit the reflexive saccade toward the peripheral target and instead generate a saccade to the mirror image location in the opposite visual field. Eye movements are recorded using an eye tracker integrated with the EEG system. The primary outcome is the error rate, calculated as the percentage of trials in which the participant fails to inhibit the reflexive saccade and looks toward the peripheral target rather than the correct mirror location.
Measured: Baseline, week12
Auditory Paired Stimuli P50 Suppression Ratio
Auditory paired stimuli are presented binaurally as 150 pairs of broadband auditory stimuli (duration 4s, 75dB). The inter-pair interval averages 9.5s (range 9-10s), and the inter-stimulus interval within each pair is 500ms. EEG is recorded continuously during the task. The P50 evoked potential is identified as the positive deflection occurring 40-80ms post-stimulus at the Cz electrode. The P50 suppression ratio is calculated as the amplitude of the response to the second stimulus (S2) divided by the amplitude of the response to the first stimulus (S1). A lower ratio indicates stronger sensory gating.
Measured: Baseline, week12
Auditory Oddball P300 Event-Related Potential Amplitude and Latency
Participants complete an auditory oddball task consisting of 567 standard tones (1000Hz) and 100 target tones (1500Hz) presented in a pseudo-random order, with an inter-stimulus interval of 1300ms. Participants are instructed to press a button upon hearing the target tone. EEG is recorded continuously. The P300 component is measured at the Pz electrode site as the largest positive deflection between 250-500ms post-stimulus. Primary outcomes are: 1) P300 amplitude (µV), defined as the peak voltage relative to a 200ms pre-stimulus baseline; and 2) P300 latency (ms), defined as the time from stimulus onset to the peak amplitude.
Measured: Baseline, week12
Resting-State EEG Spectral Power in Theta and Alpha Bands
Resting-state EEG is recorded for 5 minutes with eyes closed using a [具体设备] EEG system with electrodes placed according to the 10-20 system. Data are segmented into 2-second epochs and artifacts are removed via independent component analysis. Power spectral density (µV²/Hz) is calculated using fast Fourier transform. The primary outcomes are mean power in the theta band (4-8 Hz) and alpha band (8-13 Hz) at frontal and parietal electrode sites.
Measured: Baseline, week12
Gray Matter Volume from Structural MRI
High-resolution T1-weighted structural MRI scans are acquired using a [3T Siemens Prisma] MRI scanner. Images are preprocessed using voxel-based morphometry (VBM) with SPM12 software. Gray matter is segmented from white matter and cerebrospinal fluid. The primary outcome is the regional gray matter volume (mm³) in regions of interest, normalized for total intracranial volume.
Measured: Baseline, week12
Fractional Anisotropy from Diffusion Tensor Imaging (DTI)
Diffusion tensor imaging (DTI) data are acquired using a single-shot echo-planar imaging sequence with 30 diffusion directions (b-value = 1000 s/mm²) and one non-diffusion-weighted image (b=0). Data are preprocessed for eddy current and motion correction using FSL software. Fractional anisotropy (FA) maps are calculated, representing the directionality of water diffusion in white matter tracts. The primary outcome is the mean FA value in major white matter tracts (e.g., corpus callosum, cingulum bundle), with FA values ranging from 0 (isotropic diffusion) to 1 (completely anisotropic diffusion).
Measured: Baseline, week12
Amplitude of Low-Frequency Fluctuations (ALFF) from Resting-State fMRI
Resting-state functional MRI (fMRI) data are acquired using a gradient-echo echo-planar imaging sequence while participants are instructed to remain awake with eyes closed. Data are preprocessed including slice-timing correction, head motion correction, and spatial normalization to standard MNI space. The amplitude of low-frequency fluctuations (ALFF) is calculated as the square root of the power spectrum in the low-frequency range (0.01-0.08 Hz). The primary outcome is the mean ALFF value in predefined regions of interest, reflecting the intensity of spontaneous brain activity.
Measured: Baseline, week12
Resting-State Functional Connectivity (Seed-Based)
Using the same resting-state fMRI data described above, functional connectivity is assessed using a seed-based correlation approach. The mean time series is extracted from a seed region of interest (e.g., posterior cingulate cortex for default mode network). Pearson's correlation coefficients are calculated between the seed time series and all other voxels in the brain. Correlation coefficients are then transformed to Fisher's z-scores for normalization. The primary outcome is the strength of functional connectivity (Fisher's z) between the seed region and target brain regions.
Measured: Baseline, week12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2026
- Study start7 Feb 2023
- Primary completion1 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patients With Severe Mental IllnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 230 participants (estimated)
- Target duration
- 12 Weeks
Sponsor and investigators
- Lead sponsor
- Tianjin Anding Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07448675
- Sponsor's protocol ID
- SMI-UT
- Status last verified
- Jan 2026
- First submitted
- 19 Jan 2026
- Last updated
- 4 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness
- ClinicalTrials.gov ID
- NCT07448675
- Acronym / sponsor ID
- SMI-UT
- Conditions
- Patients With Severe Mental Illness
- Keywords
- Patients with Severe Mental Illness, cognitive dysfunction, Untreated, longitudinal follow-up, Biological Mechanism
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 230 participants (estimated)
- Lead sponsor
- Tianjin Anding HospitalUniversity, hospital or other
- Study start
- 7 Feb 2023 (actual)
- Primary completion
- 1 Jun 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 4 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with Severe Mental Illness (SMI) frequently exhibit cognitive impairment of varying degrees, involving multiple cognitive domains. These domains include working memory, attention/vigilance, verbal learning and memory, visual learning and memory, reasoning and problem-solving, processing speed, and social cognition. The severity of this impairment often predicts poorer treatment adherence and serves as a crucial indicator of a patient's capacity for independent living and social reintegration. Research into the mechanisms underlying cognitive impairment offers robust theoretical support for therapeutic interventions in SMI and remains a major focus in psychiatry. However, cognitive impairment is a complex phenomenon; studies focusing on any single cognitive dimension can only reveal partial characteristics and often lack disease specificity. Therefore, there is an urgent need to integrate multiple technical modalities, focusing on a specific biological pathway related to the symptoms of cognitive impairment, to deeply elucidate the process of its onset and to screen for reliable biomarkers. This study will recruit untreated SMI patients and healthy community controls. Upon enrollment, participants will undergo comprehensive assessments including psychiatric symptom evaluation, cognitive function testing, Electroencephalography (EEG), Magnetic Resonance Imaging (MRI), and collection of research blood samples. A follow-up assessment will be conducted at 12 weeks, re-evaluating psychiatric symptoms, cognitive functions, and EEG, while collecting follow-up blood samples and medication records. By integrating these assessment indicators, we aim to identify the potential biological mechanisms underlying cognitive dysfunction in untreated SMI patients, construct a predictive and identification model for cognitive impairment, and explore the concomitant changes in biological markers during the evolution of cognitive impairment through longitudinal follow-up, thus paving the way for prospective targeted interventions.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Weeks
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Untreated Severe Mental Illness (SMI) Patients | – | –We will enroll 150 patients who meet the following inclusion criteria: a current or past episode of a psychotic disorder meeting DSM-5 diagnostic criteria, including Schizophrenia, Schizoaffective Disorder, Acute and Transient Psychotic Disorder, Schizophreniform Disorder, Delusional Disorder, Other Specified or Unspecified Psychotic Disorder, or Bipolar Disorder with psychotic features; age between 18 and 65 years, inclusive; and willingness to participate and sign the informed consent form (ICF); in addition, untreated patients must meet the following specific criteria: no lifetime exposure to antipsychotic medication, or continuous use of antipsychotic medication for a period not exceeding 3 days, or a course of illness exceeding 5 years with no antipsychotic use in the last 5 years and a total lifetime cumulative use of antipsychotic medication of less than 30 days; traditional Chinese medicine used for treating psychotic symptoms will not be counted as antipsychotic medication. |
| Healthy Control | – | –We will include 80 healthy controls who meet the following criteria: aged 18-65 years and matched to enrolled untreated patients in terms of age, sex, educational attainment, and place of residence (urban or rural). |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This study will recruit 150 untreated severe mental illness patients and 80 healthy controls. The 150 subjects, aged 18-65, come from Tianjin Anding Hospital's inpatient/outpatient services and must consent to participate. Untreated patients must meet strict criteria: never taking antipsychotics, or taking them for ≤3 days, or >5 years of illness with <30 lifetime treatment days and no use in the last 5 years (TCM for psychosis excluded). The 80 healthy controls will be matched to patients based on age, gender, education, and residence (urban/rural).
Key inclusion criteria (2 listed)
- Aged 18-65 years;
- Matched to enrolled untreated patients in terms of age, sex, educational attainment, and place of residence (urban or rural).
Key exclusion criteria (3 listed)
- Psychotic symptoms caused by a general medical condition or substance use;
- A history of mental retardation (estimated IQ below 70), dementia, head trauma, or brain disease, a history of seizures (epilepsy), or any history of violent or suicidal tendencies;
- Any factor that prevents the participant from providing informed consent or participating in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cognitive Function
Time frame: Baseline, week12
Cognitive function will be assessed using the MATRICS Consensus Cognitive Battery (MATRICS-CN). The following domains will be measured: processing speed, verbal learning, working memory, reasoning and problem-solving, visual learning, and attention/alertness. It possesses excellent psychometric properties, correlates with functional outcomes, and is brief, easy to administer, can be used for home-based assessments, is acceptable to participants, and has domain "robustness." The MATRICS-CN has been translated into Chinese and is available for purchase from PAR, Inc.
12 secondary outcomes
Positive and Negative Symptom Scale (PANSS)
Time frame: Baseline, week12
Young Mania Rating Scale (YMRS)
Time frame: Baseline, week12
Montgomery-Åsberg Depression Rating Scale (MADRS)
Time frame: Baseline, week12
Global Assessment of Functioning (GAF) Scale
Time frame: Baseline, week12
Antisaccade Task Error Rate
Time frame: Baseline, week12
Auditory Paired Stimuli P50 Suppression Ratio
Time frame: Baseline, week12
Auditory Oddball P300 Event-Related Potential Amplitude and Latency
Time frame: Baseline, week12
Resting-State EEG Spectral Power in Theta and Alpha Bands
Time frame: Baseline, week12
Gray Matter Volume from Structural MRI
Time frame: Baseline, week12
Fractional Anisotropy from Diffusion Tensor Imaging (DTI)
Time frame: Baseline, week12
Amplitude of Low-Frequency Fluctuations (ALFF) from Resting-State fMRI
Time frame: Baseline, week12
Resting-State Functional Connectivity (Seed-Based)
Time frame: Baseline, week12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2026.
Related trials for Patients With Severe Mental Illness
RecruitingPhase 2
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
Major Depressive Disorder
Recruiting
Affective Cognitive Training in Mood Disorders and High-risk Relatives
Major Depressive Disorder (MDD), Bipolar Disorder (BD)
RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Bipolar Depression
RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Depressive Disorder, Major
RecruitingPhase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Patients With Severe Mental Illness, run by Tianjin Anding Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive Function (time frame: Baseline, week12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026; AzTrials last refreshed its copy on 7 Nov 2026.